EU/3/19/2240: Orphan designation for the treatment of non-traumatic subarachnoid haemorrhage

nicardipine

Table of contents

Overview

On 9 January 2020, orphan designation EU/3/19/2240 was granted by the European Commission to BIT Pharma GmbH, Austria, for nicardipine for the treatment of non-traumatic subarachnoid haemorrhage.

Key facts

Active substance
nicardipine
Intended use
Treatment of non-traumatic subarachnoid haemorrhage
Orphan designation status
Positive
EU designation number
EU/3/19/2240
Date of designation
09/01/2020
Sponsor

Bit Pharma GmbH
Leonhardstrasse 109
8010 Graz
Austria
Tel. +43 6643 972384
E-mail: tiziana.adage@bit-pharma.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating